Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Asthma & Allergy Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Expert Rev Clin Immunol. 2022 Jul;18(7):747-758. doi: 10.1080/1744666X.2022.2089654. Epub 2022 Jun 19.
The numerous links between allergic rhinitis and asthma have been extensively explored in the last two decades, gaining great concern within the scientific community. These two conditions frequently coexist in the same patient and share numerous pathogenetic and pathophysiological mechanisms.
We reviewed major pathophysiological, epidemiological, and clinical links between allergic rhinitis and asthma. We also provided a comprehensive discussion of allergic rhinitis treatment according to current guidelines, with a particular focus on the relevance of allergic rhinitis therapies in patients with comorbid asthma.
We believe that there are several unmet needs for our patients, however, there are promising advances forecasted for the future. Although allergic rhinitis is a recognized risk factor for asthma, a proper asthma detection and prevention plan in allergic rhinitis patients is not available. Allergen immunotherapy (AIT) represents a promising preventive strategy and may deserve an earlier positioning in allergic rhinitis management. A multidisciplinary approach should characterize the journey of patients with respiratory allergies, with an adequate referral to specialized Allergy/Asthma centers. Molecular Allergy Diagnosis may provide support for optimal AIT use. Finally, a possible evolution of biological treatment can be envisaged, mainly if biosimilars decrease such therapies' costs.
在过去的二十年中,过敏性鼻炎和哮喘之间的诸多联系已经得到了广泛的探索,引起了科学界的极大关注。这两种疾病经常在同一患者中同时存在,并具有许多共同的发病机制和病理生理机制。
我们回顾了过敏性鼻炎和哮喘之间主要的病理生理、流行病学和临床联系。我们还根据当前的指南全面讨论了过敏性鼻炎的治疗,特别关注合并哮喘的患者中过敏性鼻炎治疗的相关性。
我们认为我们的患者有一些未满足的需求,但未来有一些有前途的进展。尽管过敏性鼻炎是哮喘的一个公认危险因素,但针对过敏性鼻炎患者的适当哮喘检测和预防计划尚不可用。过敏原免疫疗法(AIT)代表了一种有前途的预防策略,在过敏性鼻炎的管理中可能需要更早的定位。多学科方法应该是呼吸道过敏患者的特征,应充分转介至专门的过敏/哮喘中心。分子过敏诊断可能为最佳 AIT 使用提供支持。最后,可以设想生物治疗的可能演变,特别是如果生物类似物降低了这些治疗的成本。